Literature DB >> 21987674

Bilateral acute iris transillumination.

Ilknur Tugal-Tutkun1, Sumru Onal, Aylin Garip, Muhittin Taskapili, Haluk Kazokoglu, Sibel Kadayifcilar, Philippe Kestelyn.   

Abstract

OBJECTIVE: To describe a series of patients with bilateral acute iris transillumination, pigment dispersion, and sphincter paralysis.
METHODS: We reviewed the medical records and clinical photographs of 26 patients seen at 5 centers in Turkey and Belgium between March 16, 2006, and July 6, 2010. Observation procedures included clinical examination, anterior segment color photography, gonioscopy, laser flare photometry, and pupillometry.
RESULTS: All 26 patients (20 women and 6 men; mean [SD] age, 43.2 [10.5] years) had bilateral involvement. Twenty-three patients (88%) had acute-onset disease with severe photophobia and red eyes. Nineteen patients (73%) had a preceding flulike illness and used systemic antibiotics, including moxifloxacin. Diagnostic laboratory workup was unremarkable. There was pigment discharge into the anterior chamber, and flare was elevated in the absence of inflammatory cells. Most patients had severe diffuse transillumination of the iris and mydriatic distorted pupils. Pupillometry revealed a compromised reaction to light. The most serious complication was an intractable early rise in intraocular pressure. Gonioscopy revealed heavy pigment deposition in the trabecular meshwork. Although symptoms were relieved promptly by application of topical corticosteroid, the median duration of pigment dispersion was 5.25 months.
CONCLUSIONS: Bilateral acute iris transillumination with pigment dispersion and persistent mydriasis is a new clinical entity that is not an ocular adverse effect of oral moxifloxacin treatment, as previously suggested. The etiopathogenesis of this entity remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987674     DOI: 10.1001/archophthalmol.2011.310

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  19 in total

1.  Oral Fluoroquinolones and the Risk of Uveitis.

Authors:  Harpal Singh Sandhu; Alexander J Brucker; Liyuan Ma; Brian L VanderBeek
Journal:  JAMA Ophthalmol       Date:  2016-01       Impact factor: 7.389

2.  [A change of eye color].

Authors:  C Paul; M Petrak; I Linares; W Sekundo
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

3.  Bilateral acute iris transillumination following systemic administration of antibiotics.

Authors:  Paris Tranos; Evangelos Lokovitis; Stelios Masselos; Nikolaos Kozeis; Magda Triantafylla; Nikolaos Markomichelakis
Journal:  Eye (Lond)       Date:  2018-03-02       Impact factor: 3.775

4.  Bilateral acute Iris transillumination after COVID-19 pneumonia.

Authors:  Murat Yüksel; Hüseyin Baran Özdemir; Şengül Özdek; Gökhan Gürelik
Journal:  Eur J Ophthalmol       Date:  2022-07-19       Impact factor: 1.922

5.  [Unusual anisocoria].

Authors:  Jan Klonner; Daniel Salchow
Journal:  Ophthalmologe       Date:  2021-06       Impact factor: 1.059

6.  Aqueous humor tyrosinase activity is indicative of iris melanocyte toxicity.

Authors:  Sarmistha Mahanty; Ankush A Kawali; Shruthi Shirur Dakappa; Padmamalini Mahendradas; Mathew Kurian; Varun Kharbanda; Rohit Shetty; Subba Rao Gangi Setty
Journal:  Exp Eye Res       Date:  2017-07-13       Impact factor: 3.467

7.  Acute iris depigmentation following systemic moxifloxacin.

Authors:  Heloisa Moraes do Nascimento; Jacqueline Martins de Sousa; Mauro Silveira de Queiroz Campos; Rubens Belfort
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

8.  Moxifloxacin and bilateral acute iris transillumination.

Authors:  Robert M Knape; Fouad E Sayyad; Janet L Davis
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-14

9.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25

10.  Bilateral acute iris transillumination: Case report.

Authors:  Cumali Degirmenci; Suzan Guven Yilmaz; Melis Palamar; Halil Ates
Journal:  Saudi J Ophthalmol       Date:  2015-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.